US Markets
Home›US Markets›Equities›Pfizer Pulls Menopause Hormone Therapy Premarin From C…
Pfizer Pulls Menopause Hormone Therapy Premarin From Canadian Market
Pfizer Inc. (NYSE:PFE) will reportedly no longer sell its hormone replacement therapy Premarin in Canada following an internal review, ending Canadian availability of both its vaginal cream and three oral tablet strengths . Pfizer Canada confirmed to Reuters on Thursday that it will supply no further batches of Premarin vaginal cream, which treats menopause symptoms and has experienced shortages in Canada since June. Menopause Drug Shortages Strain Canadian Supply The discontinuation of Premarin products, alongside shortages of certain estradiol patches, could add pressure on Canada’s menopaus
← Newer storyThe 2027 401(k) limits are here. See how much more you can save next…Older story →OpenAI launches ChatGPT Wallet, allowing its 'dots' AI agents to make…